Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013
Authors:
- 16 August 2016
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 45 (2) , 165-170
Abstract
Treatment guidelines often do not advocate testing for integrase inhibitor resistance associated mutations (IRAM) before initiation of first line ART given the extremely low prevalence of mutations found in older surveillance studies. We aimed to describe the prevalence of IRAM in Austrian patients recently diagnosed with HIV in the 5 years following introduction of integrase inhibitors and to analyse trends and factors associated with their detection. Samples of antiretroviral treatment (ART) naïve patients recently diagnosed with HIV in Austria between 2008 and 2013 were analysed for the existence of IRAM and drug penalty scores were calculated to estimate response to drugs. Demographic and virological data were extracted from a database. Descriptive and comparative statistics were used. A total of 303 samples were analysed. 78 % were male and mean age was 38 years. Overall prevalence of IRAM was 2.3 %. Six percent had at least potentially low-level resistance to raltegravir or elvitegravir, versus 1 % for dolutegravir. One primary mutation was observed (F121Y) in a patient sample from 2012 leading to 5–10-fold reduced susceptibility to raltegravir and elvitegravir. Two patients carried the accessory mutations E138K and G140A, respectively, where both lie on the Q148 pathway. No temporal trend of IRAM prevalence was observed (p = 0.16). Primary IRAM are still rarely found despite the increasing use of INSTI in Austria, but there is a potential for reduced susceptibility to these drugs in selected patients. Routine resistance testing seems prudent to avoid the consequences including accumulation of further mutations and therapeutic failure.Keywords
Funding Information
- Gilead Sciences
This publication has 22 references indexed in Scilit:
- Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in EuropeClinical Infectious Diseases, 2015
- Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.Journal of Antimicrobial Chemotherapy, 2015
- Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 InfectionThe Journal of Infectious Diseases, 2013
- Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsThe Lancet Infectious Diseases, 2013
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patientsClinical Microbiology and Infection, 2012
- In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimenAntiviral Research, 2012
- Evolution of raltegravir resistance during therapyJournal of Antimicrobial Chemotherapy, 2009
- Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase InhibitorsJournal of Virology, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008